Catalent (CTLT) Stock Rating Lowered by TheStreet
A number of other equities analysts have also recently commented on the company. UBS Group started coverage on Catalent in a report on Tuesday, October 9th. They issued a neutral rating and a $48.00 target price on the stock. JPMorgan Chase & Co. raised their target price on Catalent from $50.00 to $55.00 and gave the stock an overweight rating in a report on Wednesday, August 29th. Zacks Investment Research cut Catalent from a buy rating to a hold rating in a report on Thursday, July 26th. First Analysis raised Catalent from a neutral rating to an outperform rating and decreased their target price for the stock from $47.00 to $43.00 in a report on Wednesday. Finally, ValuEngine cut Catalent from a buy rating to a hold rating in a report on Tuesday, November 6th. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $48.11.
Shares of Catalent stock opened at $37.51 on Wednesday. Catalent has a one year low of $34.24 and a one year high of $47.87. The firm has a market capitalization of $5.48 billion, a P/E ratio of 23.59, a P/E/G ratio of 2.24 and a beta of 1.45. The company has a current ratio of 2.05, a quick ratio of 1.79 and a debt-to-equity ratio of 1.44.
In other Catalent news, SVP Lance Miyamoto sold 6,525 shares of the firm’s stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $42.50, for a total transaction of $277,312.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John R. Chiminski sold 130,545 shares of the firm’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $45.32, for a total value of $5,916,299.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 184,335 shares of company stock worth $8,161,727. Insiders own 1.40% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Atria Investments LLC grew its position in shares of Catalent by 12.6% during the third quarter. Atria Investments LLC now owns 10,208 shares of the company’s stock valued at $465,000 after purchasing an additional 1,144 shares in the last quarter. Oregon Public Employees Retirement Fund grew its position in shares of Catalent by 2.6% during the second quarter. Oregon Public Employees Retirement Fund now owns 51,962 shares of the company’s stock valued at $2,177,000 after purchasing an additional 1,299 shares in the last quarter. State of Alaska Department of Revenue grew its position in shares of Catalent by 9.7% during the third quarter. State of Alaska Department of Revenue now owns 15,648 shares of the company’s stock valued at $712,000 after purchasing an additional 1,378 shares in the last quarter. United Services Automobile Association grew its position in shares of Catalent by 6.4% during the second quarter. United Services Automobile Association now owns 23,725 shares of the company’s stock valued at $994,000 after purchasing an additional 1,418 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System grew its position in shares of Catalent by 1.2% during the third quarter. State Board of Administration of Florida Retirement System now owns 129,724 shares of the company’s stock valued at $5,909,000 after purchasing an additional 1,567 shares in the last quarter. Hedge funds and other institutional investors own 92.08% of the company’s stock.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Story: How much money do you need to begin day trading?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.